Stockscreener 앱 받기
19.72
7.59%
-1.62
시간 외 거래:
19.72
전일 마감가:
$21.34
열려 있는:
$20.845
하루 거래량:
2.84M
Relative Volume:
0.49
시가총액:
$2.07B
수익:
$2.48B
순이익/손실:
$-57.96M
주가수익비율:
-26.00
EPS:
-0.7585
순현금흐름:
$-453.97M
1주 성능:
+4.28%
1개월 성능:
-17.87%
6개월 성능:
-47.55%
1년 성능:
-85.21%
1일 변동 폭
$19.67
$21.00
1주일 범위
$18.73
$21.38
52주 변동 폭
$10.41
$132.65
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
SRPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
19.72 | 2.24B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.60 | 110.02B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.11 | 82.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.56 | 59.61B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
894.90 | 56.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
211.41 | 44.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-05 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-09-22 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 개시 | Bernstein | Mkt Perform |
| 2025-07-29 | 재확인 | H.C. Wainwright | Sell |
| 2025-07-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-07-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 개시 | Citigroup | Sell |
| 2025-07-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-07-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-21 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-07-21 | 다운그레이드 | Needham | Hold → Underperform |
| 2025-07-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-18 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-06-17 | 개시 | Wolfe Research | Peer Perform |
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Did FDA Green Light for ELEVIDYS and Pipeline Progress Just Shift Sarepta Therapeutics' (SRPT) Narrative? - simplywall.st
How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management? - Yahoo Finance
Sarepta Therapeutics (SRPT) Gets a Buy from Wells Fargo - The Globe and Mail
Why analysts raise outlook for Sarepta Therapeutics Inc. (AB3A) stockJuly 2025 Action & Entry Point Confirmation Alerts - BỘ NỘI VỤ
Sarepta (SRPT) gets FDA approval on new gene therapy study - Investorsobserver
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Tech Stocks Surge Ahead Of Thanksgiving, Robinhood Rallies 10%: What's Moving Markets Wednesday? - Benzinga
Sarepta cleared to test new safety regimen for Duchenne drug - statnews.com
Sarepta to investigate immunosuppressant Elevidys combo to avoid fatal AEs - Yahoo
Sell Rating for Sarepta Therapeutics Due to Risks in ENDEAVOR Study and Expected Share Price Decline - TipRanks
SRPT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit (PR Newswire) - Aktiellt
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership Pasadena-based Arrowhead Pharmaceuticals Inc., based in Pasadena, announced it has earned a $200 million milestone payment from Sarepta Therapeutics afte - facebook.com
Sarepta to test immunosuppressive Elevidys regimen in non-ambulatory DMD patients - FirstWord Pharma
Sarepta's Elevidys Gets Boxed Warning for ALI and ALF - CGTLive®
Sarepta gets FDA's go-ahead to study immunosuppressive Elevidys regimen in bid to reverse label restriction - Fierce Pharma
Sarepta's Stock Rises on Positive Updates on DM1 Therapy - Yahoo Finance
Sarepta Therapeutics: Hold Rating Amid ENDEAVOR Progress and Short-term Challenges - TipRanks
Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk - Benzinga
Trading the Move, Not the Narrative: (SRPT) Edition - news.stocktradersdaily.com
Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne - Lelezard
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys - Stocktwits
Sarepta (SRPT) Advances with FDA Approval for New Dystrophy Treatment Study - GuruFocus
Sarepta Therapeutics Receives FDA Approval for Dosing Levels for Elevidys Study to Treat Duchenne Muscular Dystrophy - MarketScreener
Sarepta receives FDA approval for ELEVIDYS study with enhanced immunosuppression - StreetInsider
SRPTSarepta Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Bernstein raises Sarepta Therapeutics stock price target to $20 on DMD estimates - Investing.com
Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now
Cautious Outlook on Sarepta Therapeutics Amid Early-Stage Trials and Financial Commitments - TipRanks
Sarepta shares positive safety update on DM1 asset as Arrowhead snares $200M milestone - Fierce Biotech
ELEVIDYS Label Changes and Pipeline Progress Could Be a Game Changer for Sarepta Therapeutics (SRPT) - Sahm
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - BioSpace
Arrowhead (ARWR) Secures $200M Milestone Payment from Sarepta - GuruFocus
Arrowhead Pharma secures $200M milestone from Sarepta Therapeutics - MSN
Arrowhead Pharmaceuticals to Receive $200 Million Payment From Sarepta Therapeutics for Meeting ARO-DM1 Milestone - MarketScreener
Sarepta advances phase 1/2 study of DM1 treatment, triggers milestone payment By Investing.com - Investing.com South Africa
Sarepta provides progress update for SRP-1003, its treatment for myotonic dystrophy type 1 - MarketScreener
Sarepta advances phase 1/2 study of DM1 treatment, triggers milestone payment - Investing.com
Sarepta advances SRP-1003 trial, triggers $200 million milestone payment - StreetInsider
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1 - Sarepta Therapeutics
Sarepta terminates Hansa-partnered gene therapy combination trial - Clinical Trials Arena
Tangible book value per share of Sarepta Therapeutics, Inc. – TRADEGATE:AB3A - TradingView
Sarepta Therapeutics (SRPT): Valuation Update Following ELEVIDYS Label Changes and Heightened Safety Warnings - simplywall.st
Is Sarepta Therapeutics Inc. stock overvalued by current metricsGap Down & Low Drawdown Momentum Ideas - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
In new FDA role, Pazdur will decide the future of Sarepta’s Duchenne drugs - statnews.com
Will Sarepta Therapeutics Inc. (AB3A) stock test record highs in 2025Weekly Gains Summary & Scalable Portfolio Growth Methods - newser.com
Mizuho reaffirms Sarepta Therapeutics stock with Outperform rating - Investing.com
Mizuho reaffirms Sarepta Therapeutics stock with Outperform rating By Investing.com - Investing.com Nigeria
Why Sarepta Therapeutics Inc. (AB3A) stock signals breakout potentialJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
What technical models suggest about Sarepta Therapeutics Inc.’s comeback - newser.com
Sarepta Therapeutics Inc. stock trend forecastJuly 2025 Macro Moves & Smart Allocation Stock Reports - newser.com
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.30%
1.75%
자본화:
|
볼륨(24시간):